| Bortezomib has antiproliferative and antitumor activity by inhibiting the proteasomal degradation of several regulatory ubiquitinated proteins. |
| Bortezomib has clinical activity in multiple myeloma, mantle cell lymphoma, Waldenstrom macroglobulinemia, T-cell lymphoma amyloidosis, and other lymphoproliferative disorders. |
| Ongoing studies are currently evaluating combination regimens involving either cytotoxic or targeted therapies in lymphoid malignancies. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.